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Abstract
Despite low case numbers the variant Creutzfeldt-Jakob disease epidemic poses many challenges for public health planning
due to remaining uncertainties in disease biology and transmission routes. We develop a stochastic model for variant CJD
transmission, taking into account the known transmission routes (food and red-cell transfusion) to assess the remaining
uncertainty in the epidemic. We use Bayesian methods to obtain scenarios consistent with current data. Our results show a
potentially long but uncertain tail in the epidemic, with a peak annual incidence of around 11 cases, but the 95% credibility
interval between 1 and 65 cases. These cases are predicted to be due to past food-borne transmissions occurring in
previously mostly unaffected genotypes and to transmissions via blood transfusion in all genotypes. However, we also show
that the latter are unlikely to be identifiable as transfusion-associated cases by case-linking. Regardless of the numbers of
future cases, even in the absence of any further control measures, we do not find any self-sustaining epidemics.
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Introduction
The incidence of variant Creutzfeldt-Jakob disease (vCJD) in the
UK has declined considerably since the epidemic peaked in 2000,
with currently less than 5 cases arising each year [1]. However, 15
years after the identification of the first vCJD case [2], there are still
huge uncertainties governing many aspects of the epidemiology.
Exposure via the primary route of infection – namely BSE-infected
cattle entering the human food supply – remains at very low levels
given the declining BSE epidemic in cattle and the remaining
controls in place [3]. However, there remains concern about the
possibility of future cases arising both from past exposure in
previously unaffected genotypes and through person-to-person
transmission. The latter is warranted given that 3 of the 171 cases
due to definite, probable or possible vCJD to the end of 2009 have
been linked to blood transfusions [4,5,6] and hence these could
herald the start of a potential secondary wave of cases of unknown
scale. Furthermore, it is thought that surgery and dentistry could
potentially also harbour a risk of vCJD transmission as current
decontamination methods might not be sufficient to remove
infectivity from surgical and dental instruments [7,8]. However, to
date there is no evidence that any transmissions via these
transmission routes have actually occurred.
The scale of any future waves depends in part on the existing
prevalence of infection in the population. There is currently no
simple diagnostic test for infection that can provide unambiguous
estimates of prevalence. However, there have been several studies
which have provided estimates of the prevalence of vCJD infection
in appendix and tonsil tissues. In risk assessments, a positive tissue
sample is taken as equivalent to that person being infectious
[9,10,11,12]. However, while this is the prudent approach, it is not
clear how these tests correlate with infectiousness. Furthermore, it
is still not known when in the incubation period detectable levels of
PrPSc, the abnormal form of the prion protein, begin to
accumulate in different tissues.
The prevalence of infection found in the British population
[13,14] is much higher than would be expected from the case data
alone, indicating the existence of a subclinical carrier state, during
which individuals may or may not be infectious, but will never
develop clinical disease [15]. If these sub-clinically infected people
are indeed infectious, they might play an important role in onward
transmission via blood transfusion. However, as they may never
present as cases, any transmissions caused by a sub-clinically
infected donor cannot be linked to the blood-borne transmission
route. It is therefore possible that some of the past cases that are
currently attributed to food-borne transmission were indeed
caused by human-to-human transmission.
The genotype of codon 129 of the Prion protein appears to be
important for transmission dynamics, with the two alleles
Methonine (M) and Valine (V) occurring in the population. All
probable and definite cases to date that were genotyped were
homozygous for MM, a genotype shared by about 40% of the
British population. However, in 2009 a possible case was identified
in a person of MV genotype [16]. Unfortunately, no post-mortem
was performed on this person, precluding definite diagnosis. One
explanation for the observed excess of cases in individuals with the
MM genotype is that those with MV and VV genotypes are
substantially less susceptible to vCJD disease than MMs. Under this
scenario we would not expect to see many cases in these genotypes
in the future. However, other hypotheses are conceivable, including
very long incubation periods in non-MM genotypes, potentially
resulting in a substantial number of cases arising in the future [17].
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problem for public health planning as the expected magnitude of
the future epidemic will have implications for the effort and
resources needed to control it. Here we develop a stochastic model
for vCJD spread via primary transmission through the consump-
tion of BSE contaminated beef and secondary human-to-human
transmission through red cell transfusions (but ignoring other
blood components and transmissions via surgery or dentistry),
taking into account the genetic structure of the population at
codon 129 of the PrP protein. We fit the model to the available
epidemiological data accounting for unobserved infections (pre-
clinical and sub-clinical) and unobserved transmission via red cell
transfusion to obtain the range of future scenarios consistent with
the observed epidemic to date in order to quantify the uncertainty
in the future risk of vCJD transmission in the UK and provide
appropriate inputs for public health planning.
Methods
Data
To the end of 2009 there were 167 deaths from probable or
definite vCJD in the UK, 3 of which are attributed to blood (red-
cell) transfusions, and a further 4 deaths due to possible vCJD (see
Figure 1A for the time-series, [18] for details on the classification
of cases). 153 of these cases were genotyped, with 152 MMs and 1
MV (the MV case was classified as a possible case).
The prevalence of vCJD in the British population has been
investigated by testing appendix [14] and tonsil [13] samples.
Hilton et al. found 3 positives in 11,246 appendix samples
collected between 1995 and 2000, the majority of which (91%)
came from the highest risk birth cohorts 1961–1985 (Table 1). As a
follow up to this study, the National Anonymous Tonsil Archive
was set up, aiming to collect 100,000 pairs of tonsils from 2004
onwards. No positive samples have been found through testing
with dual enzyme immune assay in the 85,000 samples tested by
March 2010. However, in a sub-sample of 10,000 tissues tested
using immuo-histochemistry, one follicle in a single sample tested
positive using two different antibodies. Here we use the prevalence
data from the original appendix study, but exclude the data from
the NATA study for the model fitting as the most precautionary
figure for risk management purposes as advised by the Spongiform
Encephalopathy Advisory Committee [19].
In the framework of the TMER (Transfusion Medicine
Epidemiology Review) study [20] the cohort of patients who have
received blood transfusions from donors that later developed vCJD
is tracked. To date, 3 cases were attributed to transmission through
blood transfusions, as the patients had received a red cell unit from
a donor who later developed clinical disease. A further infection is
thought to have occurred in a person of MV genotype who died 5
years after the transfusion in question without developing any
symptoms of vCJD, but whose spleen tested positive in the post-
mortem [21]. Two further vCJD cases potentially share a blood
donor, who remains alive 20 years after the first donation but
could nevertheless be the transmission source for both cases.
However, due to incomplete medical records this cannot be
confirmed, and taking this into account it is also possible that this
link between the two cases is a chance event [22]. This potential
link between these cases highlights that if indeed the proportion of
subclinical infections is high, as the prevalence data suggest, and
sub-clinically infected people are as infectious as those with pre-
clinical infection, we would be able to identify only a small
proportion of blood transfusion transmissions, as any transmission
from donor to recipient where donor or recipient are sub-clinically
infected cannot be detected. This means that theoretically, cases
that are currently being attributed to primary transmission could
potentially have been caused by blood transfusions.
While the fate of the whole cohort who have received
transfusions from known pre-clinical donors (duration of survival
post transfusion, and the development or not of clinical symptoms)
sheds light on the transmissibility of vCJD via blood transfusions,
the success of the transmission process depends on several
parameters, such as the timing of the onset of infectivity in the
donor, the level of infectivity, the susceptibility of the recipient and
the duration of the incubation period in the recipient, which are
difficult to disentangle with the numbers of transfusions implicat-
ed. Therefore we do not use these data to restrict the input ranges
of our parameters, but rather fit our model to the 3 cases identified
to have been caused by blood transfusions.
In order to reduce the risk of transmission via red cell
transfusion, leuko-depletion of red cell units, i.e. removal of white
blood cells, was introduced in 1998. This is thought to reduce the
infectivity of blood by approximately 40% [23], however, as a
single red cell unit may contain several thousand infectious doses,
this reduction of infectivity might not have any impact at all on
transmission. Following the identification of the first red cell
transfusion associated case in 2003, since 2004 all recipients of
blood transfusions have been excluded from donating blood. If this
donor ban is effective and blood transfusions are the only viable
human-to-human transmission route, this should break the cycle of
onward transmissions and only allow a first generation of blood
transfusion transmissions to occur. Both of these interventions are
included in our model.
The dietary exposure to the BSE agent is estimated to have
peaked in 1989, after which the specified bovine offal ban was
introduced therefore reducing the number of infectious cattle
entering the human food chain despite the continuing rise of the
BSE epidemic itself, which peaked in 1993, see Figure 1B and
[24].
Interestingly, the age distributions of red cell donors and
recipients differ substantially: While the peak age for donations is
between the early 40 s and the mid 50 s, with people over 70 years
of age excluded from donating blood, the majority of red cells is
used in the elderly, with a peak in the 70 s (see Figure 1C and D
and [10]). These data, including the annual number of
transfusions and the average number of red cell units given in a
single transfusion dependent on the recipient’s age, are taken from
[25].
In our model, we assume a constant population size of 60
million with demographics that are stable over time. Data on the
age structure of the UK population are taken from UK census
data [10] (Figure 1E). Approximately 39% of the population are of
MM genotype, 50% of MV and 11% of VV genotype [26].
We calculate the age dependent excess mortality associated with
red cell transfusions (Figure 1F) from the probability of surviving
until k years post-transfusion Sa,k,post [25] and the survival data for
the general population Sa,general as ma,k~1{Sa,k,post
Sa,general
Sazk,general
,
where a indexes age. As the majority of the excess mortality
happens shortly after the transfusion, we use the 2-year post
transfusion excess mortality and implement this excess mortality to
occur at the time of the transfusion, therefore effectively
preventing clinical disease and further onward transmission from
any person not surviving the transfusion.
Mathematical Model
We developed a stochastic simulation model for the transmis-
sion of vCJD in the British population which includes as
transmission routes primary transmission through consumption
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human transmission via red cell transfusions. This model is similar
in structure to the deterministic model used in [10]. However, here
we structure the population not only with respect to age (allowing
for yearly age groups), but also to genotype, taking into account
the 3 different genotypes at PRP codon 129, MM, MV and VV.
Furthermore, in the stochastic individual-based framework we can
keep track of the infection history and therefore classify the arising
secondary cases into identifiable or unidentifiable with respect to
the transmission route, depending on whether the blood donor in
question did or did not develop clinical vCJD.
The natural history of the disease is modelled as a SEIR-type
model, see Figure 2, which differentiates between primary (food-
borne) and secondary (blood-borne) transmission. Furthermore,
Figure 1. Input data. A Time series of observed cases by genotype and presumed transmission route, B time-dependence of the exposure of the
British population to the BSE agent, C age-dependent annual blood donation rates, D age-distribution of red cell use, E Age-dependent survival
probability, F age-dependent excess mortality associated with red cell transfusions.
doi:10.1371/journal.pone.0015626.g001
Uncertainty in the Tail of the vCJD Epidemic
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15626infection can lead to clinical disease after a lengthy incubation
period, or be sub-clinical, in which case the infected person will
continue to live to the end of their natural life span without any
symptoms. The proportion v of infections that are sub-clinical
varies between primary and secondary transmission. Upon
infection, a person enters a non-infectious latent stage, followed
by an infectious stage and eventually, death from either vCJD or
natural causes (also allowing for age-dependent competing risks of
death for pre-clinical infection).
For pre-clinical infection, the durations of the latent and
infectious stages are sampled from gamma distributions for each
individual, resulting in a gamma distributed total incubation
period from infection to death from vCJD. Gamma distributions
are chosen for ease of modelling as they only have two parameters
and convenient summation properties, yet show a sufficient
flexibility in shape to warrant a good model fit.
We parametrise the gamma distribution of the total incubation
period by the mean D and shape parameter k and specify the
proportion a of the incubation period that should be infectious.
From this we then find the mean and shape parameters of the
gamma distributions for the latent and infectious stages as
Dlat~ 1{a ðÞ D, Dinf~aD, klat~ 1{a ðÞ k and kinf~ak. For sub-
clinical infection, the latent stage is assumed to follow the same
distribution as that of pre-clinical infection, but the infectious stage
lasts until the end of the natural life span.
The population is stratified into 3 different genotypes, and here
we allow the mean incubation period, but not the shape
parameter, to vary between the different genotypes. Furthermore,
the mean incubation period for secondary (blood-borne) trans-
mission deviates from that for primary transmission by a factor
IPb, but again retaining the same shape parameter, such that the
mean incubation period for genotype g with secondary infection is
Dg,2~IPbDg,1, where Dg,1 is the mean incubation period for
genotype g with primary infection.
For primary transmission, we fit a strong age-dependence of
susceptibility, Yp a ðÞ , which could be caused by biological or by
dietary factors or a combination of both [27,28]. This is again
modelled to follow a gamma distribution, yielding a good model
fit to the data. For secondary transmission, we assume no age
dependence in biological susceptibility, such that the age profile of
infections is entirely determined by the age distribution of trans-
fusion recipients. We allow different susceptibilities jg for the
different genotypes (setting jMM~1). In the absence of compelling
data suggesting otherwise, we assume that the genotype dependence
of susceptibility is independent of transmission route. An alternative
assumption that does not introduce yet more unknown parameters
into the model would be to assume that all genotypes are equally
susceptible to secondary transmission, as was done by [10],
essentially ignoring the genetic structure of the population.
Primary Infection
The risk of primary infection varies by age, genotype and
calendar time via exposure to BSE-infected animals entering the
food supply. The infection rate from primary transmission
l1 a,g,t ðÞ for a person of genotype g, aged a at time t is given by
l1 a,g,t ðÞ ~NpgYp a ðÞ Jpg t ðÞjg:
Here, N is the total UK population size and pg is the proportion of
the population of genotype g. g t ðÞis the time-dependent exposure
of the population to the BSE agent and Jp is the overall level of
infectivity of BSE via the dietary route, normalised to the expected
number of clinical cases arising from primary transmission in the
MM genotype group, including past and future cases. A
proportion v1 of infections are sub-clinical and the remaining
proportion 1{v1 of infections are pre-clinical.
Person-to-person transmission via red cell transfusion
People receive red cell transfusions according to a Poisson
process with age-dependent rates. The number of units they
receive also depends on their age. The probability that a patient of
age a and genotype gbecomes infected given that they receive a
red cell transfusion is given by
pb a,g ðÞ ~ 1{ 1{bjgxb(t)
   ba ðÞ hi
1{ma ðÞ ,
where ba ðÞis the mean number of red cell units given in a
transfusion to a person of age a, b is the transmissibility, xb t ðÞis
the prevalence of infectivity in the blood pool and ma is the age-
dependent excess mortality associated with the transfusion,
assuming as a reasonable approximation that transfusion-associ-
ated excess mortality occurs close to the time of transfusion.
The rate of infection from red cell transfusions for a person of
age a and genotype g is then given by
l2 a,g,t ðÞ ~NpgtbYb a ðÞ pb a,g ðÞ
Table 1. Details of the batches in the prevalence study by
Hilton et al. [14].
Birth cohort Number of samples Number positive
1941–1960 574 0
1961–1985 10278 3
1986–1990 394 0
All tissues were removed between 1995 and 2000.
doi:10.1371/journal.pone.0015626.t001
Figure 2. Flowchart of the model. Thepopulation is stratifiedby age
(a) and genotype (g). S= susceptible, E1/2= exposed via primary/
secondary infection, I1/2,pre= preclinically infectious for primary/second-
ary infection, I1/2, sub= subclinically infectious for primary/secondary
infection, D1= death from primary vCJD disease, Dnatural= death from
other causes than vCJD, D2,id.= death from identifiable transfusion
associated vCJD disease, D2,unid= death from transfusion transmitted
vCJD disease, but transmission route unidentifiable, v1= proportion
of subclinical infection for primary transmission, v2= proportion of
subclinical infection for transfusion associated transmission.
doi:10.1371/journal.pone.0015626.g002
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red cell transfusion-associated transmissions, the proportion of
subclinical infections is denoted by v2.
Individuals are assumed to donate blood at random time points
according to a Poisson process, where the donation rate only
depends on the age of the donor. The prevalence of infectivity
xb t ðÞin the national blood pool at any time is assumed to equal
that in the donor population (i.e. the prevalence in the whole
population weighted by the age-dependent donation rates),
xb t ðÞ ~
X
a
Ia t ðÞ
Na
Wb a ðÞ ,
where Ia t ðÞis the number of infectious individuals of age a at time
t, Na is the population size of age a, and Wb a ðÞis the age-
dependent donation rate.
The model is implemented as a branching process in continuous
time, neglecting the depletion of susceptibles given that the overall
prevalence of infection is estimated to be low. The infection events
from primary and secondary infection follow Poisson processes
with time-dependent rates l1 t ðÞ ~
P
a,g
l1 a,g,t ðÞ and l2 t ðÞ ~
P
a,g
l2 a,g,t ðÞ , such that the time of the next infection event is
drawn from a Poisson distribution with rate l1 t ðÞ zl2 t ðÞ . At each
infection event, the transmission route and age and genotype of
the infected person are determined according to the relative
contributions of the individual rates. The latent and incubation
periods are drawn from the respective gamma-distributions and
the prevalence of infection in the population and in the blood pool
over time is updated. Depending on the transmission route, and
whether the case develops clinical disease, the count of deaths is
updated at the appropriate time in the future.
Model Parameterisation
Although we use all available data to parameterise the model,
there are still many model parameters that are inherently unknown,
mostly relating to the disease biology. In the model fitting process,
we sample these from reasonable ranges, in order to assess which
ranges of model parameters produce simulations consistent with the
observed outbreak and to gain insight into the potential scale of the
future epidemic. A summary of these unknown parameters and the
ranges considered here is given in Table 2. For the parameters
which were estimable the ranges were chosen such that they well
covered the region containing the bulk of the posterior distributions,
or cut off at values beyond which the dynamics of the model would
not be altered. For instance, the range for the incubation period
shape parameter was cut off at 100. A shape parameter this high
corresponds to a highly peaked distribution, and any higher shape
parameter would not influence the model output. Most of the non-
estimable parameters have a theoretically possible range that is
restricted to the interval 0–1, which was fully explored. Only the
multiplier for the incubation period of secondary transmission could
theoretically take values higher than the limit of 2 we have used
here. However, any higher value would mean that the incubation
period for blood-borne transmission is more than twice as long as
that of primary food-borne transmission, which appears unlikely.
As a baseline scenario we assume that leuko-depletion results in
a 40% reduction in the transmissibility b from 1998 onwards. We
assume that the donor ban is only 90% effective. Both sensitivity
and specificity of the test used in the appendix study are assumed
to be 100%. Sensitivity analyses to these assumptions can be found
in Supplementary Material S1.
While the time-dependence of the dietary exposure to BSE g t ðÞ
can be obtained from data on the BSE epidemic, the overall level
of infectivity Jp can only be gleaned from the number of primary
human cases that have occurred to date; this parameter is varied in
the model simulations. Furthermore, the relative susceptibility
of the different genotypes jg is unknown. We normalise the
susceptibility of the MM genotype to jMM~1, and vary the
susceptibilities of the other genotypes between 0 and 1.
In order to reproduce the observed age-profile of cases we use
an age-dependent susceptibility to primary infection Yp a ðÞ , which
we assume to be gamma-distributed, with mean yp,mean and shape
parameter yp,shape, both of which are varied in the fitting process.
The transmissibility via red cell transfusions b, the proportion of
the incubation period that is infective, a, as well as the proportion
of infections that are sub-clinical for primary and secondary
transmission, v1 and v2, respectively, are unknown and varied
across their possible range from 0 to 1.
Model fitting
To fit the model to the time-series of the observed epidemic,
including all 171 deaths from definite, probable and possible vCJD
observed to the end of 2009 as well as the prevalence estimates
from the appendix study [14], we use a Bayesian framework [29].
As there is little external information on which to base priors, we
assume uniform (non-informative) priors for all our parameters.
We therefore proceed by sampling the parameter space of the
unknown parameters using Latin Hypercube sampling [30]. For
each set of parameter values, we perform N~80 stochastic
simulations and for each simulation calculate the likelihood of this
parameter set based on these simulations. We weight each para-
meter set by its likelihood across the 80 stochastic realisations to
obtain the posterior distribution for the parameters and for the
outputs of interest (time-series of cases by transmission route).
The likelihood factorises into a factor for the time-series and its
age distribution, a factor for the number of identified blood cases, a
factor for the genotype distribution and a factor for the prevalence,
L~LTSLbloodLgenotypeLprev:
For the time-series likelihood LTS, we stratify the observed
incidence into 3 age groups, the cut-off points of 26 and 33 years
roughly corresponding to the tertiles of the observed age-at-death
distribution. We then group the incidence into year-groups, such
that the number of cases dobs a,t ðÞ observed in each age-group a
and year-group t is at least 5. The full time-series likelihood is
given by the product over all compartments,
LTS~P
a,t
La,t:
For each compartment we assume that both observed and
simulated deaths accumulate according to a Poisson process with
rate la,t. From the N simulation runs per parameter set we infer
the maximum likelihood estimate of this rate as ^ l la,t~
1
N
X N
j~1
dj a,t ðÞ . The likelihood factor for this age- and year-group
is then given by
La,t~
^ l l
dobs a,t ðÞ
a,t e{^ l la,t
dobs a,t ðÞ !
,
Similarly, we assume that the number of transfusion associated
cases accumulates according to a Poisson process with rate lb, with
maximum likelihood estimate ^ l lb~
1
N
X N
j~1
dj,id,b, where dj,id,b is the
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therefore have
Lblood~
^ l l
dblood,obs
b e{^ l lb
dblood,obs!
,
with the number of observed transfusion associated cases dblood,obs.
We assume that the number of cases in the different genotypes
arise according to a multinomial distribution. We infer the
proportion pg of cases of genotype g based on the N simulation
runs per parameter set via maximum likelihood as
^ p pg~
P N
j~1
dj g ðÞ
P N
j~1
P
g 
dj g  ðÞ
,
where dj g ðÞ is the number of deaths in genotype g and simulation
run j, and the possible genotypes g are MM, MV and VV. The
genotype likelihood Lgenotype is then given as
Lgenotype dMM,obs,dMV,obs,dVV,obs ðÞ ~
P
g
dg,obs
 !
!
P
g dg,obs!
   P
g
^ p p
dg,obs
g ,
From the prevalence study using appendix tissues [14], we have
information on 3 batches of tested tissue samples, which were
collected between 1995 and 2000. For each batch i, we know the
range of birth cohorts, the time-span over which samples were
collected, the total number Ni of samples and the number ni of
positive samples, see Table 1. For each batch, we calculate the
prevalence of infectiousness (assuming that being infectious
coincides with testing positive) in the relevant age-range and
time-span across all simulation runs as ^ p pi~
P
a,t
P N
j~1
Ij a,t ðÞ
P
a,t
P N
j~1
Nj a,t ðÞ
, where
Ij a,t ðÞ is the number of infectious people in the relevant age and
year group, and Nj a,t ðÞ is the population size in the age- and year
group in simulation run j. The probability of observing the
number of positives observed in batch i, given the simulated
prevalence ^ p pi in the tested sub-population, is that of a binomial
distribution,
Lprev,i~
Ni
ni
  
^ p p
ni
i 1{^ p pi ðÞ
Ni{ni:
The overall prevalence likelihood is the product over all
batches, Lprev~P
i Lprev,i.
The results shown here are based on 1592100 sets of parameter
values, sampled uniformly from the parameter ranges given in
Table 2.
Results
A good fit to the total number of past cases, the number of past
identifiable red cell transfusion associated cases and the distribu-
tion of cases to date by genotype was obtained (Figure 3). The total
number of past cases obtained in the simulations is clustered
around the observed value of 171 cases. The vast majority of these
simulated cases are in the MM genotype, with small numbers of
cases in the MV or VV genotype, matching the observed number
of cases in these genotypes (1 and 0, respectively). At present, 3
cases have been associated with red-cell transfusion as the likely
route of infection, well within the range recovered in the
simulations. Of note, the number of past cases that are attributed
to unidentifiable red-cell transfusion associated transmission (if one
of either the donor or recipient has not yet developed symptoms)
Table 2. Model parameters, prior distributions (all uniform within the range quoted) and medians (95% credibility intervals) of the
fitted parameter values for those parameters that were estimable.
Description Name Prior distribution
Posterior median (95%
credible interval)
Transmissibility via primary transmission Jp U[80, 230] 173 (144–199)
Mean incubation period for MMs infected via primary transmission DMM U[10,13.5] 11.6 (10.9–12.2)
Incubation period shape parameter k U[5, 100] 45 (23–81)
Mean age-dependent susceptibility/exposure for infection via primary transmission Yp,mean U[10, 40] 17.9 (15.9–20.0)
Age-dependent susceptibility/exposure shape Yp,shape U[1,15] 3.8 (2.3–6.6)
Mean incubation period for MVs infected via primary transmission DMV U [10, 80] 34 (19–73)
Mean incubation period for VVs infected via primary transmission DVV U[10, 80] 52 (26–77)
Relative susceptibility of MVs compared to MMs jMV U[0, 1] NE
Relative susceptibility of VVs compared to MMs jVV U[0, 1] NE
Transmissibility via red cell transfusions b U[0, 1] NE
Ratio of incubation period for red cell transfusion-associated transmissions compared to
incubation period for primary transmission
IPb U[0, 2] NE
Proportion of the incubation period that individuals are infectious a U[0, 1] NE
Proportion of primary infections that are subclinical v1 U[0, 1] NE
Proportion of secondary infections that are subclinical v2 U[0, 1] NE
Basic reproduction number R0 n/a 0.0056 (0.0003–0.0146)
NE = not estimable.
doi:10.1371/journal.pone.0015626.t002
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majority of scenarios). This suggests that to date primary
transmission via consumption of BSE-infected cattle is most likely
the main transmission route.
Figure 4 shows the range of the simulated prevalence in the age
groups tested in the appendix study [14]. This falls for the most
part within the 95% confidence bounds from this study. However,
the simulated prevalence tends to be towards the lower end of the
95% confidence intervals estimated in the appendix survey.
Estimates for the model parameters are shown in Table 2,
alongside the range explored for each parameter. Parameters
determining primary transmission in the MM genotype (the group
in which the vast majority of cases were observed) are well
characterised and can be estimated with a reasonable degree of
precision. The model parameters relating to red cell transfusion
associated transmission as well as those relating to transmission in
other genotypes cannot be estimated at present due to the small
number of cases observed for these transmission routes and
genotypes. Thus we can only vary them within reasonable ranges
to get likely scales of the total outbreak size.
The estimated mean incubation period (defined here as the time
from infection to death) for infection via primary transmission in
the MM genotype is similar to previous estimates obtained from
primary transmission models [28,31] and is approximately the
delay from the peak of exposure to BSE which occurred in 1989/
1990 to the peak in the vCJD deaths which occurred in 2000. Age-
dependent susceptibility/exposure is estimated to be highest in
teenagers and young adults in line with previous estimates [27,28].
Whilst only one possible vCJD case has been observed in a non-
MM genotype, this information does give some bounds on the
mean incubation periods in these other genotypes in conjunction
with their relative susceptibility compared to the MM-genotypes
(Figure 5). The lack of cases in the VV genotype implies that short
incubation periods in this genotype (i.e. comparable to that for the
MM genotype) are only consistent with the observed epidemic if
the susceptibility is highly suppressed. This is similar to the
situation in the MV genotype. However, here very long mean
incubation periods are also unlikely due to the recent possible case.
Note that for longer incubation periods, the projected number of
clinical cases is limited by the competing risk of death from other
causes.
Table 2 also shows values of the basic reproduction number R0,
calculated based on the values of the input parameters for every
simulation run (see Supplementary Material S1). R0 can be
interpreted as the average number of secondary infections a typical
infected case will generate during their infectious period in the
absence of any saturation effects, and is therefore a threshold
quantity: For values smaller than 1, each new generation of cases
will be smaller than the previous generation, and the epidemic will
die out with certainty even without any further control measures.
However, there might be a substantial number of cases before this
extinction occurs, particularly for values of R0 only a little less than
1. For values larger than 1 on the other hand, every subsequent
generation of cases is on average larger than the previous, leading
to exponential growth and a self-sustaining epidemic unless
stochastic extinction occurs early on. For any of the scenarios
Figure 3. Posterior distribution of simulated case numbers to the end of 2009. A all cases, B identifiable blood cases, C unidentifiable blood
cases, D MM cases, E MV cases, F VV cases.
doi:10.1371/journal.pone.0015626.g003
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calculated in the presence of the control measures of leuko-
depletion and the donor ban, is much lower than this threshold,
therefore precluding the potential for a self-sustaining epidemic
and limiting the number of future cases substantially. The reason
that our projections of future cases might appear large given the
small values of R0 is that through the food borne transmission
route, a large initial number of infectives (including the sub-clinical
carriers) have been introduced into the population.
Figure 6 shows the posterior distribution of the time series of
cases in total and stratified by transmission route as well as
genotype whilst the median and 95% credible intervals for the
cumulative number of future cases by genotype are given in
Table 3 (note however that these cases are predicted to occur over
the next hundred years). The projected time series of cases shows a
double-peaked pattern. The first peak, which occurs around the
year 2000, describes the past epidemic attributable mostly to
exposure via primary transmission in the MM genotype and has a
reasonably tight credibility range as this is fitted to data. Panel A
also shows the observed number of cases, which agree well with
the model fit of the time series. The second peak is broader, lasting
from now (2010) to around 2080, with a peak value reached
between 2020 and 2035, depending on the relative contribution of
secondary cases in the MM genotype and primary cases in the MV
genotype, with a most likely peak incidence of approximately 10
cases per year. However it should be borne in mind that the
associated uncertainty for these projections is large, with the 95%
credibility interval of the posterior distribution of the projected
peak annual incidence ranging from 1 to 65 cases. While it
therefore remains entirely possible that there will not be any
observed secondary epidemic, the possibility of a secondary peak
cannot be discounted despite the current low level of incidence.
If the secondary peak does occur, our projections suggest that it
will mostly consist of transfusion-transmitted cases, mainly in the
MM genotype, but to a lesser extent also in the MV genotype.
However, our projections also suggest that we are unlikely to
identify this as the route of transmission via linking of donor-
recipient pairs due to the presence of subclinical infections and
competing risks of death in the older group of transfusion recipients.
Furthermore, there might also be a number of primary cases in the
MV genotype, whereas the total number of cases in the VV
genotype is expected to be low. While for the future primary cases
generally transmission already has occurred, for the bulk of the
transfusion associated peak the transmission is predicted to happen
in the future (see Supplementary Material S1). These cases would
therefore be preventable if appropriate and effective control
measures, such as a blood test for vCJD or an effective method to
remove infectivity from any blood products, were available.
It might be surprising at first to see that the number of projected
future cases in the MV genotype is of the same order of magnitude
as that in the MM genotype, whereas in the past, the vast majority
of cases were observed in the MM genotype, with only one
possible MV case. However, comparing the projected total
numbers of future cases in the different genotypes is slightly
misleading: In the MM genotype the primary epidemic is
essentially over, whereas if any substantial number of primary
MV cases occurs, this will be in the future due to a longer
incubation period in this genotype. Therefore we should rather
compare the projected numbers of transfusion-associated cases in
the MM and MV genotypes, and here the MV cases make only
about a third to a quarter of the MM cases, and the lower bound is
close to 0, indicating that the possibly most intuitive scenario with
very few future cases in the MV genotype is perfectly consistent
with the model projections. However, due to uncertainties in
parameters such as the incubation period, we cannot exclude a
considerably larger epidemic in this genotype either. The same
argument of course applies also to VV cases, but due to the small
proportion of the VV genotype in the population, the numbers
involved are much smaller than for the MV genotype.
Discussion
When the first vCJD cases were reported in the late 1990s, the
small numbers combined with lack of knowledge of both the
potential transmission routes and key epidemiological parameters
meant that projections of the future epidemic were highly
uncertain [24,32]. Following the peak in cases in 2000, and their
subsequent decline to low numbers, it has for several years been
possible to characterise the oral transmission route in the MM
genotype and estimate associated epidemiological parameters with
a reasonable degree of precision [28,31]. However, with small
numbers of cases now arising in different genotypes and via other
transmission routes (3 cases of MM genotype attributed to blood
transfusions since 2003 and reports of a possible vCJD case in a
person of MV genotype), there remain concerns about the
potential for a second epidemic wave.
Figure 4. Posterior distribution of the prevalence of detectable PrPSc by batch as defined in the survey [14]. A 1941–1960 cohort, B
1961–1985 cohort, C 1986–1990 cohort. The vertical dotted lines indicate exact binomial confidence intervals for the prevalence based on the
number of samples tested and the number of positives. For A and C, the upper end of the confidence interval lies to the right of the scale due to the
smaller number of samples in these batches.
doi:10.1371/journal.pone.0015626.g004
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model in a Bayesian framework, combining the transmission via
food-borne and red cell transfusion associated transmission with a
differentiation with respect to genotype. Our results indicate that
we can expect only a small number of future cases to arise in both
the MV and VV genotypes through primary transmission. This is
because the infection risk is assumed to have been very low indeed
for several years and so efficient primary transmission to these
genotypes is now only possible in combination with rather long
incubation periods, such that a substantial proportion of those
infected would reach the end of their natural life span before
succumbing to clinical disease. Larger numbers of future cases are
possible in all genotypes if efficient transmission occurs though
red-cell transfusion. However, even these numbers are limited by
the numbers of individuals and the age-profile of those that receive
transfusions [10,33]. Our results suggest that if a second epidemic
does arise, this is likely to evolve over a number of decades. Our
best estimate for the annual incidence is low with up to 10 cases
occurring annually, although the credibility intervals are wide due
to large uncertainties in many of the key parameters governing
transmission.
Despite the rather long time-scale of this potential second wave,
we did not find any scenarios which led to a self-sustaining
epidemic as classified by the basic reproduction number R0.I n
fact, the R0 values are so low that even if both leuko-depletion and
the donor ban were totally ineffective they would reach values of
Figure 5. Joint posterior density of relative susceptibility and total number of cases with mean incubation period. A and B: relative
susceptibility vs mean incubation period, C and D: total number of cases vs mean incubation period. A and C for MV genotypes, B and D for VV
genotypes. Dark = high density, light = low density.
doi:10.1371/journal.pone.0015626.g005
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found the potential for a self-sustaining epidemic for some
combination of parameter values in the absence of any control
measures. These results were based on fitting to 2 transfusion
associated cases up to 2006, whereas here we are fitting to 3 cases
up to 2009, taking into account a number of years during which
no transfusion associated cases have been observed. Furthermore,
some of the assumptions underlying the earlier work were more
pessimistic, whereas here we have refined the model to be more
realistic, such as allowing for a delay between infection and the
onset of infectivity, a lower susceptibility in non-MM genotypes
and the use of several red cell units in a single transfusion, reducing
the values of the basic reproduction number further.
One assumption implicit in our model simulations concerns the
age dependence of susceptibility/exposure to infection. To fit the
age distribution of the primary epidemic, as in previous work
[27,28], we fit a strong age dependence in susceptibility/exposure.
To date there have been too few secondary cases to fit a
distribution to this age profile and we have therefore assumed that
for blood-borne transmission susceptibility is independent of age.
This might be the case if the age-distribution of cases via primary
transmission occurred due to differences in exposure rather than
biological susceptibility per se, although evidence for this is limited
[34]. Furthermore, animal studies have suggested that one
mechanism for biological susceptibility may be age-related
changes in the gut [35] and thus it is possible that all ages would
Figure 6. Median and posterior distributions of projected time series. A Total number of cases, B transfusion associated cases that can be
identified through donor-recipient pairing, C unidentifiable transfusion associated cases and D to F number of cases in the different genotypes, MM,
MV and VV, respectively. Diamonds = observed epidemic, solid line = median, greyscale graduations: 10% range to 90% range.
doi:10.1371/journal.pone.0015626.g006
Table 3. Estimated medians (95% credibility intervals) of the cumulative number of future cases from 2010 to 2179 by genotype
and transmission route.
Transmission route
Genotype Total Primary Identifiable blood Unidentifiable blood
All genotypes 390 (84–3000) 100 (11–220) 17 (1–220) 260 (30–2700)
MM 200 (20–2200) 1 (0–6) 12 (0–160) 190 (16–2000)
MV 160 (4–980) 91 (1–210) 4 (0–57) 51 (1–760)
VV 13 (0–85) 7 (0–36) 0 (0–5) 5 (0–51)
Numbers are rounded to two significant digits.
doi:10.1371/journal.pone.0015626.t003
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Regardless, even if biological susceptibility did occur via all
transmission routes, this remains a reasonable assumption if the
infectivity in a single red cell unit is very high. However, for lower
transmissibility, including age-dependent susceptibility would
reduce the secondary peak considerably given the lack of overlap
between those that appear most susceptible to date (teenagers and
young adults) and the age distribution of transfusion recipients
[25].
We also investigated sensitivity to our assumptions regarding the
effectiveness of the control policies in place (see Supplementary
Material S1). None of the alternative assumptions investigated
changed the overall dynamics significantly, however, the upper
limit of the credibility intervals of the projected future epidemic
size varied for different scenarios. If leuko-depletion is ineffective
in preventing transmissions via red cell transfusions we would
expect the secondary outbreak to be up to twice as large, whereas
a less effective donor ban had very little effect on the outbreak size.
This is because the majority of red cell transfusion cases are caused
by people who were themselves infected via the oral transmission
route and are therefore not subject to the donor ban. If the test
sensitivity of the prevalence test is lower, the true population
prevalence is higher than measured in the appendix study, leading
to more secondary transmission and therefore potential for a larger
secondary outbreak.
In summary, given that there are no further known transmission
routes efficient enough that they could lead to a self-sustaining
epidemic, the variant CJD epidemic in the UK is likely to continue
with a low level annual incidence for a lengthy period of years to
decades. Whilst any projections of future case numbers are highly
uncertain, reflecting the current uncertainties in key transmission
parameters for the genotypes and transmission routes in which we
have not seen many cases as yet, the timescales involved are fairly
insensitive to these highly uncertain parameters. Despite the
inherent large uncertainty our results are important for public
health planning: The current low level of annual incidence
appears to suggest that the epidemic is nearly over. However,
while this might be the case, a secondary peak remains a
possibility, and this has to be taken into account when decisions
are made about the introduction or withdrawal of control
measures.
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